Trial Profile
Study to evaluate infusion related reactions associated with rituximab or ocrelizumab and their effect on the cytokine profiles of patients with Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 27 Apr 2018 Results (n=40) assessing characterize the cytokine changes associated with antiCD20 therapies, were presented at the 70th Annual Meeting of the American Academy of Neurology.
- 20 Nov 2017 New trial record
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis